In vitro and in vivo effects of BT563, an anti-interleukin-2 receptor monoclonal antibody |
| |
Authors: | T. VanGelder C. R. Daane L. M. B. Vaessen C. J. Hesse W. Weimar B. Mochtar A. H. M. M. Balk |
| |
Affiliation: | Department of Internal Medicine, University Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands;Thorax Center, University Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands |
| |
Abstract: | Abstract BT563, a murine anti-IL-2R MoAb, was found to be more potent than anti-Tac in inhibiting proliferation in the mixed lymphocyte reaction. Results obtained with 33 B3.1 in these experiments were similar to those with BT563. The anti-IL-2R MoAb 2A3 was shown to be a suitable agent for monitoring the effect of BT563 on peripheral blood. IL-2R-positive cells were not detected in peripheral blood samples from 1 h after the first dose until 8 days after the last dose. Plasma trough levels were measured in patients receiving 5 or 10 mg daily. The administration of BT563 to allograft recipients did not lead to clinically significant side effects. |
| |
Keywords: | Interleukin-2 receptor BT 563 MLR Rejection prophylaxis |
|
|